

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ficoxil 227 mg chewable tablets for dogs  
Firocoxib

**2. STATEMENT OF ACTIVE SUBSTANCES**

Firocoxib 227 mg

**3. PHARMACEUTICAL FORM**

Chewable Tablet

**4. PACKAGE SIZE**

10 tablets  
30 tablets  
60 tablets  
100 tablets  
180 tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATION(S)**

**7. METHOD AND ROUTE OF ADMINISTRATION**

For oral use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

Halved or quartered tablets should be returned to the open blister pocket, inserted into the outer carton and given within 7 days.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Industrial Veterinaria SA  
Calle Esmeralda, 19  
08950 Esplugues de Llobregat  
Spain

**16. MARKETING AUTHORISATION NUMBER**

Vm 36547/5015

**17. MANUFACTURER’S BATCH NUMBER**

Batch {number}

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**Blisters**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ficoxil 227 mg chewable tablets  
Firocoxib



**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Industrial Veterinaria SA

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

Batch {number}

**5. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

## **B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:  
Ficoxil 227 mg Chewable Tablets for Dogs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER  
AND OF THE MANUFACTURING AUTHORISATION HOLDER  
RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Industrial Veterinaria SA  
Calle Esmeralda, 19  
08950 Esplugues de Llobregat  
Spain

Manufacturer responsible for batch release:

aniMedica Herstellungs GmbH  
Im Südfeld 9  
48308 Senden-Bösensell Germany

aniMedica GmbH  
Im Südfeld 9  
48308 Senden-Bösensell Germany

Industrial Veterinaria, S.A.  
Esmeralda, 19  
08950 Esplugues de Llobregat (Barcelona) Spain

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ficoxil 227 mg Chewable Tablets for Dogs  
Firocoxib

**3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS**

Each tablet contains:

**Active substance:**

Firocoxib            227 mg

**Excipients:**

Red iron oxide (E172)            0.525 mg  
Yellow iron oxide (E172)        0.225 mg

Biconvex rosaceous round tablets with a double groove on one side without inscriptions.

Tablets can be divided into 2 or 4 equal parts

**4. INDICATIONS**

For the relief of pain and inflammation associated with osteoarthritis in dogs.

For the relief of post-operative pain and inflammation associated with soft-tissue, orthopaedic and dental surgery in dogs.

## **5. CONTRAINDICATIONS**

Do not use in pregnant or lactating bitches.

Do not use in animals less than 10 weeks of age or less than 3 kg body weight.

Do not use in animals suffering from gastrointestinal bleeding, blood dyscrasia or haemorrhagic disorders.

Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).

Do not use in known cases of hypersensitivity to the active substance or to any of the excipients.

## **6. ADVERSE REACTIONS**

Emesis and diarrhoea have occasionally been reported. These reactions are generally of a transitory nature and are reversible when the treatment is stopped. Renal and/or hepatic disorders have been reported in very rare cases in dogs administered the recommended treatment dose. Rarely, nervous system disorders have been reported in treated dogs.

If adverse reactions like vomiting, repeated diarrhoea, faecal occult blood, sudden weight loss, anorexia, lethargy, degradation of renal or hepatic biochemistry parameters occur, use of the product should be stopped and the advice of a veterinarian should be sought. As with other NSAIDs, serious adverse effects can occur and, in very rare cases, may be fatal.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system {national system details}.

## **7. TARGET SPECIES**

Dogs.



## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Administer 5 mg firocoxib per kg bodyweight once daily.


For the reduction of post-operative pain and inflammation, the animals can be dosed starting approximately 2 hours before surgery for up to 3 consecutive days as needed. Following orthopaedic surgery and depending on the response observed, treatment using the same daily dosing schedule may be continued after the first 3 days, upon judgement of the attending veterinarian.

For oral use as per table below which is intended as a guideline for administering the veterinary medicinal product at the recommended dose.

Body weight (kg)	Number of tablets by size		mg/kg range
	57 mg	227 mg	
3.0 – 5.5	½		5.2 – 9.5
5.6- 7.5	¾		5.7 – 7.6
7.6-10	1	or ¼	5.7 – 7.5
10.1- 13	1 ¼		5.5 – 7.1
13.1 - 16	1 ½		5.3 – 6.5
16.1-18.5	1 ¾		5.4 – 6.2
18.6-22.5		½	5.0 – 6.1
22.6-34		¾	5.0 – 7.5
34.1-45		1	5.0 – 6.7
45.1-56		1 ¼	5.1 – 6.3
56.1-68		1 ½	5.0 – 6.1
68.1-79		1 ¾	5.0 – 5.8
79.1-90		2	5.0 – 5.7

 = ¼ Tablet   
  = ½ Tablet   
  = ¾ Tablet   
  = 1 Tablet

Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing.



## **9. ADVICE ON CORRECT ADMINISTRATION**

Tablets can be administered with or without food. Do not exceed the recommended dose.

Duration of treatment will be dependent on the response observed. As field studies were limited to 90 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the veterinarian.

## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Any remaining tablet portion should be returned to the blister and given at the next administration within 7 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

## **12. SPECIAL WARNING(S)**

Special warnings for each target species:

None.

Special precautions for use in animals:

As the tablets are flavoured, they should be stored in a safe place out of the reach of animals.

The recommended dose, as indicated in the dosing table, should not be exceeded.

Use in very young animals, or animals with suspected or confirmed impairment of renal, cardiac or hepatic function may involve additional risk. If such use cannot be avoided, those dogs require careful veterinary monitoring.

Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided.

Use this product under strict veterinary monitoring where there is a risk of gastrointestinal bleeding, or if the animal previously displayed intolerance to NSAIDs. Renal and/or hepatic disorders have been reported in very rare cases in dogs administered the recommended treatment dose. It is possible that a proportion of such cases had sub-clinical renal or hepatic disease prior to the commencement of therapy. Therefore, appropriate laboratory testing to establish baseline renal or hepatic biochemistry parameters is recommended prior to and periodically during administration.

The treatment should be discontinued if any of these signs are observed: repeated diarrhoea, vomiting, faecal occult blood, sudden weight loss, anorexia, lethargy, degradation of renal or hepatic biochemistry parameters.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This product may be harmful following accidental ingestion.

In order to prevent children from accessing the product, tablets should be administered and stored out of sight and reach of children. Halved or quartered tablets should be returned to the open blister pocket and inserted into the outer carton.

Laboratory studies in rats and rabbits have shown evidence that firocoxib has the potential to effect reproduction and to induce malformations in fetuses. Pregnant women or women who are intending to become pregnant should administer the product with caution.

Wash hands after use of the product.

In the event of accidental ingestion of one or more tablets, seek medical advice immediately and show the package leaflet or the label to the doctor.

Pregnancy and lactation:

Do not use in pregnant or lactating bitches.

Laboratory studies in rabbits have shown evidence of maternotoxic and foetotoxic effects at dose rates approximating the recommended treatment dose for the dog.

Interaction with other medicinal products and other forms of interaction:

Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before the commencement of treatment with the product. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Gastrointestinal tract ulceration may be exacerbated by corticosteroids in animals given non-steroidal anti-inflammatory drugs.

Concomitant treatment with molecules displaying action on renal flow, e.g. diuretics or Angiotensin Converting Enzyme (ACE) inhibitors, should be subject to clinical monitoring. Concurrent administration of potentially nephrotoxic drugs should be avoided as there might be an increased risk of renal toxicity. As anaesthetic drugs may affect renal perfusion, the use of parenteral fluid therapy during surgery should be considered to decrease potential renal complications when using NSAIDs peri-operatively.

Concurrent use of other active substances that have a high degree of protein binding may compete with firocoxib for binding and thus lead to toxic effects.

Overdose (symptoms, emergency procedures, antidotes):

In dogs ten weeks of age at the start of treatment at dose rates equal or greater to 25 mg/kg/day (5 times the recommended dose) for three months, the following signs of

toxicity were observed: bodyweight loss, poor appetite, changes in the liver (accumulation of lipid), brain (vacuolisation), duodenum (ulcers) and death. At dose rates equal or greater to 15 mg/kg/day (3 times the recommended dose) for six months, similar clinical signs were observed, albeit that the severity and frequency were less and duodenal ulcers were absent.

In those target animal safety studies, clinical signs of toxicity were reversible in some dogs following cessation of therapy.

In dogs seven months of age at the start of treatment at dose rates greater than or equal to 25 mg/kg/day (5 times the recommended dose) for six months, gastrointestinal adverse effects, i.e. vomiting were observed.

Overdose studies were not conducted in animals over 14 months of age.

If clinical signs of overdosing are observed, discontinue treatment.

#### Incompatibilities:

Not applicable.

### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

### **14. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### **15. OTHER INFORMATION**

Package sizes:

- 1 cardboard box containing 1 blister of 10 tablets (10 tablets).
- 1 cardboard box containing 3 blisters of 10 tablets (30 tablets).
- 1 cardboard box containing 6 blisters of 10 tablets (60 tablets).
- 1 cardboard box containing 10 blisters of 10 tablets (100 tablets).
- 1 cardboard box containing 18 blisters of 10 tablets (180 tablets).

Not all pack sizes may be marketed.

*Gavin Hall*  
Approved: 25 November 2025